Weiterbehandlung von jungen Erwachsenen mit Epilepsie

ZUSAMMENFASSUNG

Hintergrund Der Übergang zum Erwachsenenalter stellt eine besonders vulnerable Episode in der individuellen Entwicklung des Menschen dar. Bei Menschen mit Epilepsie können krankheitsassoziierte Faktoren die Entwicklungschancen maßgeblich stören, weshalb bei der Weiterbehandlung junger Erwachsener mit Epilepsie nicht nur medizinische Aspekte berücksichtigt werden dürfen.

Fragestellung Systematische Darstellung relevanter Aspekte in Transition und Transfer bei Epilepsien sowie gezielte Beleuchtung von Faktoren, die in der Weiterbehandlung von jungen Erwachsenen mit Epilepsie relevant sind.

Material und Methoden Zusammenfassung und Diskussion von Original- und Übersichtsarbeiten sowie von Expertenempfehlungen.

Ergebnisse Aufgrund der hohen Inzidenz von Epilepsien in den ersten beiden Lebensjahrzehnten, kommt dem strukturierten Übergang in der klinischen Praxis eine entscheidende Bedeutung zu. Krankheitsassoziierte Faktoren führen bei dieser Patientengruppe zu Besonderheiten, die langfristige Auswirkungen auf die individuelle Entwicklung haben und in therapeutische Konzepte einbezogen werden sollten. Ein strukturierter Übergang in die Erwachsenenmedizin sowie die Berücksichtigung verschiedener Schlüsselfaktoren, wie z. B. der Verlauf spezifischer Epilepsiesyndrome, die Wirkung von Antiepileptika sowie soziale Aspekte und individuelle Lebenskonzepte, sind wichtige Aspekte in der Behandlung junger Erwachsener mit Epilepsie.

Diskussion Bei jungen Erwachsenen mit Epilepsie sollten verschiedene Aspekte, die über die medizinische Behandlung hinausgehen, berücksichtigt und in die individuelle Behandlungsstrategie einbezogen werden.

ABSTRACT

Background The transition from adolescence to adulthood is a particularly vulnerable episode in the individual development. In people with epilepsy, disease-associated factors can significantly disrupt developmental opportunities. Therefore, not only medical aspects must be considered in the further treatment of young adults with epilepsy.

Objectives Systematic presentation of relevant aspects in transition and transfer in epilepsy as well as targeted illumination of factors relevant in the further treatment of young adults with epilepsy.

Materials and methods Summary and discussion of original work and reviews as well as expert’s opinions.

Results Due to the high incidence of epilepsies in the first two decades of life, structured transition has a crucial importance in clinical practice. Disease-associated factors lead to special features in this patient group, which have long-term effects on the individual development and should be included in therapeutic concepts. A structured transition to adult medicine as well as the consideration of several key factors, such as the course of specific epilepsy syndromes, effects of antiepileptic drugs as well as social aspects and individual life concepts, are important aspects in the treatment of young adults with epilepsy.

Conclusions Various aspects beyond medical treatment should be considered and included in the individual treatment strategy of young adults with epilepsy.

Schlüsselwörter

Epilepsie - Anfälle - Transition - Transfer – junge Erwachsene

Keywords

Epilepsy - seizures - transition - transfer – young adults

Publication History

Article published online:
08 November 2022

• Literatur

• 1 Fiest K, Sauro KM, Wiebe S. et al Prevalence and incidence of epilepsy. Neurology 2017; 88: 296-303
• 2 Sharma N, O’Hare K, Antonelli RC. et al Transition care: future directions in education, health policy, and outcomes research. Acad Pediatr 2014; 14 (02) 120-127
• 3 Blum R, Hirsch D, Kastner TA. et al A consensus statement on health care transitions for young adults with special health careneeds. Pediatrics 2002; 110: 1304-1306
• 4 Nabbout R, Camfield P. Transition in adulthood: The challenge of epilepsies. Epilepsia 2014; 55 (Suppl. 03) 1-2
• 5 Scheidt-Nave C, Ellert U, Thyen U. et al Prävalenz und Charakteristika von Kindern und Jugendlichen mit speziellem Versorgungsbedarf im Kinder- und Jugendgesundheitssurvey (KiGGS) in Deutschland. Bundesgesundheitsbl – Gesundheitsforsch – Gesundheitsschutz 2007; 50: 750-756
• 6 Staa AL van, Jedeloo S, Meerten J van. et al Crossing the transition chasm: experiences and recommendations for improving transitional care of young adults, parents and providers. Child Health Care Dev 2011; 37 (06) 821-832
• 7 Crowley R, Wolfe I, Lock K. et al Improving the transition between paediatric and adult healthcare: a systematic review. Arch Dis Child 2011; 96: 548-553
• 8 Wirrell E, Wong-Kisiel LC, Nickels KC. Seizure outcome after AED failure in pediatric focal epilepsy: impact of underlying etiology. Epilepsy Behav 2014; 34: 20-24
• 9 Wirrell EC, Camfield CS, Camfield PR. et al Long-term prognosis of typical childhood absence epilepsy: remission or progression to juvenile myoclonic epilepsy. Neurology 1996; 47: 912-918
• 10 Nabbout R, Andrade D, Bahi-Buisson N. et al Outcome of childhood-onset epilepsy from adolescence to adulthood: Transition issues. Epilepsy Behav 2017; 69: 161-169
• 11 Olsson I, Campenhausen G. Social adjustment in young adults with absence epilepsies. Epilepsia 1993; 34: 846-851
• 12 Schneider-von Podewils F, Gasse C, Geithner J. et al Clinical predictors of the long-term social outcome and quality of life in juvenile myoclonic epilepsy: 20–65 years of follow-up. Epilepsia 2014; 55 (02) 322-330
• 13 Chu-Shore CJ, Major P, Camposano S. et al The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010; 51: 1236-1241
• 14 Chiron C, Marchand MC, Tran A. et al Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndromede dicated trial. STICLO study group. Lancet 2000; 356 9242 1638-1642
• 15 Balestrini S, Sisodiya SM. Audit of use of stiripentol in adults with Dravet syndrome. Acta Neurol Scand 2017; 135 (01) 73-79
• 16 Marson AG, Al-Kharusi AM, Alwaidh M. et al SANAD study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007; 24 369[9566] 1000-1015
• 17 Pellock JM, Carman WJ, Thyagarajan V. et al Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review. Neurology 2012; 79: 1482-1489
• 18 Ladino LD, Hernández-Ronquillo L, Téllez-Zenteno JF. Management of antiepileptic drugs following epilepsy surgery: A meta-analysis. Epilepsy Research 2014; 108 (04) 765-774
• 19 Lamberink HJ, Otte WM, Geerts AT. et al Individualised prediction model of seizure recurrence and long-term outcomes after withdrawal of antiepileptic drugs in seizure-free patients: a systematic review and individual participant data meta-analysis. Lancet Neurol 2017; 16: 523-531
• 20 Contento M, Bertaccini B, Biggi M. et al Prediction of seizure recurrence risk following discontinuation of antiepileptic drugs. Epilepsia 2021; 62: 2159-2170
• 21 Yang W, Zhang X, Long J. et al Prediction of the recurrence risk in patients with epilepsy after the withdrawal of antiepileptic drugs. Epilepsy & Behavior 2020; 110: 107156
• 22 He RQ, Zeng QY, Zhu P. et al Risk of seizure relapse after antiepileptic drug withdrawal in adult patients with focal epilepsy. Epilepsy Behav 2016; 64: 233-238
• 23 Ramos-Lizana J, Aguirre-Rodríguez J, Aguilera-López P. et al Recurrence risk after withdrawal of antiepileptic drugs in children with epilepsy: a prospective study. Eur J Paediatr Neurol 2010; 14: 116-124
• 24 Geithner J, Schneider F, Wang Z. et al Predictors for long-term seizure outcome in juvenile myoclonic epilepsy: 25–63 years of followup. Epilepsia 2012; 53: 1379-1386
• 25 Kadel J, Bauer S, Hermsen A. et al Use of Emergency Medication in Adult Patients with Epilepsy: A Multicentre Cohort Study from Germany. CNS Drugs 2018; 32: 771-781
• 26 Hommet C, Sauerwein HC, De Toffol B. et al Idiopathic epileptic syndromes and cognition. Neurosci Biobehav Rev 2006; 30: 85-96
• 27 Motamedi G, Meador K. Epilepsy and cognition. Epilepsy Behav 2003; 04: 25-38
• 28 Aldenkamp A, Arends J. The relative influence of epileptic EEG discharges, short nonconvulsive seizures, and type of epilepsy on cognitive function. Epilepsia 2004; 45: 54-63
• 29 Witt JA, Helmstaedter C. How can we overcome neuropsychological adverse effects of antiepileptic drugs?. Expert Opinion on Pharmacotherapy 2017; 18: 551-554
• 30 Witt JA, Elger CE, Helmstaedter C. Adverse cognitive effects of antiepileptic pharmacotherapy: each additional drug matters. Eur Neuropsychopharmacol 2015; 25 (11) 1954-1959
• 31 von Podewils F. Psychosocial outcome in juvenile myoclonic epilepsy (Janz syndrome) and other genetic generalized epilepsies. Z Epileptol 2020; 33: 151-156
• 32 Baker GA, Brooks J, Buck D. et al The stigma of epilepsy: a european perspective. Epilepsia 2000; 41: 98-104
• 33 Gabriel D, Ventura M, Samões R. et al Social impairment and stigma in genetic generalized epilepsies. Epilepsy Behav 2020; 104: 106886
• 34 Cengiz GF, Tanik N. Who is more important in stigmatization, family or friends?. Epilepsy Behav 2020; 104: 106880